Antigen Receptor Manufacturers, Suppliers & Companies
-
Manufacturerbased in Florham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Celularity - Model CAR-T - Chimeric Antigen Receptor T Cells
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an ...
CONTACT SUPPLIER -
Technologybased in Paris, FRANCE
We are a biotech company combining microfluidics, digitalization and bioengineering to make high quality biological therapies at affordable cost and minimized environmental impact. Therapeutic cells can multiply in the patient's body. This allows ...
Chimeric Antigen Receptor CAR-T
In healthy patients T cells detect and kill sick cells. Cancer cells escape T cells recognition thanks to mutations. CAR-T cells (T cells equipped with a Chimeric Antigen Receptor) are artificially hardcoded to ...
CONTACT SUPPLIER -
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
Alphageneron Pharmaceuticals is a clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer cells (NK) cell and antibody-based therapies to treat cancer. Our seasoned team of biopharmaceutical executives, ...
Chimeric Antigen Receptor (CAR) NK Cells
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based ...
CONTACT SUPPLIER -
Technologybased in São Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
Model CAR-T - Chimeric T Cell Antigen Receptor Therapy
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than ...
CONTACT SUPPLIER -
Technologybased in Cambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
VOR - Model VCAR33 (CD33) - CD33-Directed Chimeric Antigen Receptor T Cell
Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site ...
CONTACT SUPPLIER -
Technologybased in San Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Model DAR T - Dimeric Antigen Receptor-T Cell
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell ...
CONTACT SUPPLIER -
Manufacturerbased in San Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
Model FT596 - T Cells Engineered with Chimeric Antigen Receptors (CARs)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical ...
CONTACT SUPPLIER -
Manufacturerbased in Mont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
Celyad - Model CYAD-221 - Allogeneic CAR T Candidate
CYAD-221 is a preclinical short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. CYAD-221 is engineered to co-express a CD19 chimeric antigen receptor and an shRNA ...
CONTACT SUPPLIER -
Manufacturerbased in Cambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
CAR T-Cell Therapy
CAR T-cell therapy is the engineering of a patient’s T cells, a type of white blood cell. A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen ...
CONTACT SUPPLIER -
Manufacturerbased in Menlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
CONTACT SUPPLIER -
Manufacturerbased in Oxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
GlyMab - Model Anti-glycan mAb - Antibodies for Cancer
Glycosylation is a post-translational modification that occurs inside the cell and results in the addition of sugar motifs, “glycans”, to proteins and lipids that are, in most cases, destined for the cell surface. These glycan structures ...
CONTACT SUPPLIER -
Manufacturerbased in Piscataway, NEW JERSEY (USA)
Genscript is the world’s leading biotech company providing life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, we are internationally recognized as a leading ...
-
Technologybased in Carlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
Chimeric - Model CHM 1301 (CLTX CAR NK) - NK Cell Derived Allogeneic Therapies
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen ...
CONTACT SUPPLIER -
Manufacturerbased in New York, NEW YORK (USA)
Aurora Biopharma is founded on a single mission to revolutionize the treatment of cancer, by using the human body’s immune system. Aurora is developing state-of-the-art cancer immunotherapy, a form of adoptive cell transfer called Chimeric Antigen ...
-
Technologybased in Mawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
-
Manufacturerbased in Holytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Model Co-Stim CAR-T - Chimeric Co-stimulatory Receptor T Cells
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous gamma delta T cell receptor (TCR), and combines it ...
CONTACT SUPPLIER -
Manufacturerbased in Basel, SWITZERLAND
We are a Biologics CDMO (Contract Development and Manufacturing Organization) offering our clients more than just development and manufacturing. In everything we do, we go one step beyond expectations. We enable our customers to exceed their goals ...
-
Manufacturerbased in London, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
HEMO-CAR-T Immunotherapy
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using ...
CONTACT SUPPLIER -
Manufacturerbased in Oxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
ProM2 - Model MHC Class II - Monomers, Biotinylated
or solution phase immunoassays for measuring interactions of predefined MHC Class II-peptide complexes with ligands such as monoclonal antibodies, recombinant T cell receptors, or other binding scaffolds, e.g. for use in screening ...
CONTACT SUPPLIER -
Technologybased in Berkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
CAR-T - Cell Therapies for Hematologic Cancers
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you